GlassScriptPhysician profile
Seth Jesse Lofgreen
NPI 1801259023
$4,542.69
in general payments reported to CMS, 2019-2025
27 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.18 · 2021: $521 · 2022: $500 · 2023: $1,193 · 2024: $953 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.66 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.81 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $326.35 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $296.37 | 2021-2025 | |
| Leo Pharma INC. | $286.86 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $286.69 | 2021-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $274.42 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $204.63 | 2022-2024 | Sotyktu |
| Ucb, INC. | $194.84 | 2023-2025 | Bimzelx, Cimzia |
| Almirall LLC | $192.32 | 2021-2025 | Klisyri, Seysara |
| Regeneron Healthcare Solutions, INC. | $186.75 | 2023-2025 | Dupixent, Libtayo |
| Pfizer INC. | $184.57 | 2021-2025 | |
| Genzyme Corporation | $156.83 | 2023-2025 | |
| Galderma Laboratories, L.P. | $134.74 | 2023-2025 | Nemluvio |
| Incyte Corporation | $133.19 | 2022-2025 | Opzelura |
| Organogenesis INC. | $96.24 | 2025 | Puraply Wound Matrix, Novachor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $88.63 | 2023-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $68.08 | 2021-2023 | Valchlor |
| Organon LLC | $45.59 | 2025 | |
| Journey Medical Corporation | $45.02 | 2022 | |
| Convatec INC. | $44.56 | 2024-2025 | |
| Blueprint Medicines Corporation | $41.58 | 2024 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $40.53 | 2024 | Zoryve |
| Amgen INC. | $39.23 | 2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.05 | 2021-2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.47 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $22.83 | 2025 | |
| Krystal Biotech INC | $18.51 | 2023 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Lofgreen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.